Breast cancer patients are coming forwards and alleging that the chemotherapy drug Taxotere (docetaxel) has caused them long term hair loss, a side effect the maker did not obviously disclose.
Taxotere, produced by Sanofi-Aventis and sold in the U. S. since 1999, is utilized to treat patients with advanced or metastasized breast cancer, along with other types of tumor. Most chemotherapy drugs are known to cause short-term hair loss, with curly hair growing back soon after treatment ends.
Unfortunately, that has not been the case with Taxotere users diagnosed with alopecia universalis, a condition characterized by a loss of all body hair that might never return. To hire a best hair loos injury lawyer you can browse online.
Morgan & Morgan lawyers are filing personal injury lawsuits with respect to Taxotere users against Sanofi-Aventis, seeking reimbursement for pain and suffering and other damages allegedly due to the medication. When you’ve experienced permanent hair thinning after getting treated with Taxotere, please contact me now to get a free case inspection.
FDA Issued Taxotere Warning at 2015, However Other Nations Knew Earlier
Back in March 20-16 that an Ohio breast cancers patient filed case (Carson v. Sanofi SE, et al, case number 1:2016-cv-00165 at the U.S. District Court for the Northern District of Ohio), found that Sanofi Aventis had cautioned patients and physicians at Europe since 2005 and Canada at 2012 in regards to the probability of lasting hair thinning from Taxotere, but waited until a month following the FDA’s information upgrade to frighten Americans.